{"doc_id": "si-2025-0350-reg-1", "parent_doc_id": "si-2025-0350", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "1. These Regulations may be cited as the Data Protection Act 2018 (Section", "text_raw": "1. These Regulations may be cited as the Data Protection Act 2018 (Section \n38(4)(b)) (Inquiry into the Licensing and Use of Sodium Valproate in Women \nof Child-Bearing Potential in the State) Regulations 2025. \n\nRevocation", "text_norm": "1 regulation may cited data protection act 2018 (section 38(4)(b)) (inquiry licensing use sodium valproate woman child-bearing potential state) regulation 2025 revocation", "start_char": 797, "end_char": 1023, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-2", "parent_doc_id": "si-2025-0350", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "2. The Data Protection Act 2018 (Control of Data for the Inquiry into the", "text_raw": "2. The Data Protection Act 2018 (Control of Data for the Inquiry into the \nHistorical Licensing and Use of Sodium Valproate) Regulations 2024 (S.I. No. \n752 of 2024) are revoked. \n\nDefinitions", "text_norm": "2 data protection act 2018 (control data inquiry historical licensing use sodium valproate) regulation 2024 (s.i no 752 2024) revoked definition", "start_char": 1023, "end_char": 1218, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-3", "parent_doc_id": "si-2025-0350", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "In these Regulations –", "text_raw": "3. \n\nIn these Regulations – \n\n“Act of 2018” means the Data Protection Act 2018 (No. 7 of 2018); \n\n“inquiry” means the inquiry into the licensing and use of sodium valproate in \nwomen of child-bearing potential in the State, approved by decision of the \nGovernment on 11 July 2023; \n\n“inquiry chair” means the person appointed by the Minister to conduct the \ninquiry and provide a final report to the Minister; \n\n“Minister” means the Minister for Health; \n\n“relevant person” means – \n\n(a) \n\nthe inquiry chair, \n\n(b) \n\ncounsel for the inquiry, \n\n(c) \n\n(d) \n\n(e) \n\n(f) \n\n(g) \n\na legal advisor to the inquiry chair, \n\na member of staff of the inquiry, \n\na clinical psychologist providing services to the inquiry chair in \nconnection with the inquiry, \n\nthe Minister, and \n\nany other person acting for, appointed by or working under the \ndirection of the inquiry chair or the Minister in connection with \nthe inquiry; \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 25th July, 2025. \n\n \n \n \n \n \n\f[350] 3 \n\n“relevant task”, in relation to the inquiry, means a task carried out by a relevant \nperson in connection with the terms of reference; \n\n“terms of reference” means the terms of reference of the inquiry, which terms \nare set out in the Schedule. \n\nApplication of Regulations", "text_norm": "3 regulation - act 2018 mean data protection act 2018 (no 7 2018) inquiry mean inquiry licensing use sodium valproate woman child-bearing potential state approved decision government 11 july 2023 inquiry chair mean person appointed minister conduct inquiry provide final report minister minister mean minister health relevant person mean - (a) inquiry chair (b) counsel inquiry (c) (d) (e) (f) (g) legal advisor inquiry chair member staff inquiry clinical psychologist providing service inquiry chair connection inquiry minister person acting appointed working direction inquiry chair minister connection inquiry notice making statutory instrument published iris oifigiuil 25th july 2025 350 3 relevant task relation inquiry mean task carried relevant person connection term reference term reference mean term reference inquiry term set schedule application regulation", "start_char": 1218, "end_char": 2537, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-3", "parent_doc_id": "si-2025-0350", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "3. These Regulations apply to personal data –", "text_raw": "3. These Regulations apply to personal data – \n\n(a) \n\n(b) \n\nprocessed by the inquiry, and \n\nin respect of which the inquiry chair and the Minister are joint \ncontrollers. \n\nProcessing – public interest", "text_norm": "3 regulation apply personal data - (a) (b) processed inquiry respect inquiry chair minister joint controller processing - public interest", "start_char": 2537, "end_char": 2741, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-4", "parent_doc_id": "si-2025-0350", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "4. Subject to the General Data Protection Regulation and the Act of 2018,", "text_raw": "4. Subject to the General Data Protection Regulation and the Act of 2018, \nthe processing by a relevant person of personal data to which these Regulations \napply, and which is necessary and proportionate for the performance of a \nrelevant task carried out in the public interest by a relevant person, is hereby \nspecified. \n\nCircumstances in which personal data may be processed", "text_norm": "4 subject general data protection regulation act 2018 processing relevant person personal data regulation apply necessary proportionate performance relevant task carried public interest relevant person hereby specified circumstance personal data may processed", "start_char": 2741, "end_char": 3122, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-5", "parent_doc_id": "si-2025-0350", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "5. Without prejudice to the generality of Regulation 4, the circumstances in", "text_raw": "5. Without prejudice to the generality of Regulation 4, the circumstances in \nwhich personal data to which these Regulations apply may be processed shall \ninclude the performance by a relevant person of such relevant tasks as the inquiry \nchair considers necessary and proportionate to enable the inquiry to – \n\n(a) \n\n(b) \n\ninquire into the matters set out in the terms of reference, or \n\nreport or make recommendations to the Minister in accordance \nwith the terms of reference. \n\nPersons to whom personal data may be disclosed", "text_norm": "5 without prejudice generality regulation 4 circumstance personal data regulation apply may processed shall include performance relevant person relevant task inquiry chair considers necessary proportionate enable inquiry - (a) (b) inquire matter set term reference report make recommendation minister accordance term reference person personal data may disclosed", "start_char": 3122, "end_char": 3653, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-6", "parent_doc_id": "si-2025-0350", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "6. Personal data to which these Regulations apply may be disclosed to a", "text_raw": "6. Personal data to which these Regulations apply may be disclosed to a \nrelevant person in accordance with such policies and procedures as may be \nprovided for under Regulation 7. \n\nConditions of processing", "text_norm": "6 personal data regulation apply may disclosed relevant person accordance policy procedure may provided regulation 7 condition processing", "start_char": 3653, "end_char": 3863, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-7", "parent_doc_id": "si-2025-0350", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "7. (1) The inquiry chair shall prepare and implement policies and procedures", "text_raw": "7. (1) The inquiry chair shall prepare and implement policies and procedures \n\nto provide for the processing of personal data under these Regulations. \n\n(2) Without prejudice to the generality of paragraph (1), the policies and \n\nprocedures referred to in that paragraph shall provide for the following: \n\n(a) \n\nthe use of secure storage, passwords, encryption and other \nmethods to ensure personal data can only be accessed by the \ninquiry chair or by a relevant person authorised by the inquiry \nchair to access that data; \n\n \n \n \n \n \n\f4 [350] \n\n(b) \n\nthe use of controls to ensure that personal data are only disclosed \nto – \n\n(i) \n\na relevant person, or \n\n(c) \n\n(d) \n\n(ii) \n\na person entitled or permitted by law to receive that \npersonal data; \n\nthe determination of appropriate storage periods for personal data \nor classes of personal data; \n\nthe treatment, including erasure where relevant, of personal data \nor classes of personal data at the expiry of the storage periods \nreferred to in subparagraph (c); \n\n(e) \n\ndata minimisation, including the use of anonymisation and \npseudonymisation where appropriate. \n\n(3) The inquiry chair shall – \n\n(a) \n\nreview the policies and procedures referred to in paragraph (1) on \na regular basis, and \n\n(b) update those policies and procedures as the inquiry chair \n\nconsiders appropriate. \n\n \n \n \n\fSchedule \nInquiry into the licensing and use of sodium valproate in women of childbearing potential in the State \n\n[350] 5 \n\nTerms of Reference \n\nPurpose and focus of the Inquiry \n\nThe purpose of the inquiry is as follows: \n\n• To provide a voice to persons with a diagnosis of foetal valproate \nspectrum disorder (FVSD), or progressing through the diagnostic \npathway, their mothers and other family members. \n\n• To document the regulation of sodium valproate in the State from initial \nlicensing until the present day and the corresponding practices and \ncontrols in place relating to the prescribing and dispensing of this product \nto women of child-bearing potential throughout this time. \n\n• To develop a timeline of significant developments in the scientific \n\nknowledge relating to the teratogenicity of sodium valproate. \n\n• To assess the Irish health system’s current capacity to respond, \ndisseminate and implement measures that address safety issues relating \nto use of sodium valproate in women of child-bearing potential, and to \nprovide recommendations regarding same, with consideration of \nrelevance to other anti-seizure medications (ASMs). \n\n• To assess the adequacy of services and supports currently provided to \nthose diagnosed with FVSD and their caregivers, and to provide \nrecommendations regarding same if identified. \n\n International Classification of Diseases, Version 11, as adopted by the WHO Assembly in \nMarch 2019, defines Fetal Valproate Spectrum Disorder (code LD2F.03 ) as: Fetal valproate \nspectrum disorder (FVSD) and Fetal valproate syndrome (FVS) describe the range of signs and \nsymptoms which occur as a consequence of exposure to sodium valproate or valproic acid in \nthe womb. A wide range of physical anomalies occur at increased frequency, including spina \nbifida, major and minor limb abnormalities, oral clefting, cardiac defects, hypospadias, and \njoint laxity. A characteristic pattern of facial dysmorphism is frequently present, especially \nnotable in early childhood. Neurodevelopmental problems including reduced IQ, poorer \nlanguage and motor development, increased rates of autistic spectrum disorder and attention \ndeficit hyperactivity disorder are observed in up to 40% of those exposed. Vision problems \nsuch as myopia and astigmatism are also common. Risks are dose dependent and the impact on \nthe brain may be seen at lower doses than those required for physical development alterations. \n\n \n \n \n \n \n \n \n \n \n \n\f6 [350] \n\nReview Phase \n\n• Establish a timeline on the licensing and use of sodium valproate in \nwomen of child-bearing potential and the emergence of evidence \nregarding its teratogenicity since it was first licensed in the State until the \npresent day by review of the following:", "text_norm": "7 (1) inquiry chair shall prepare implement policy procedure provide processing personal data regulation (2) without prejudice generality paragraph (1) policy procedure referred paragraph shall provide following (a) use secure storage password encryption method ensure personal data accessed inquiry chair relevant person authorised inquiry chair access data 4 350 (b) use control ensure personal data disclosed - (i) relevant person (c) (d) (ii) person entitled permitted law receive personal data determination appropriate storage period personal data class personal data treatment including erasure relevant personal data class personal data expiry storage period referred subparagraph (c) (e) data minimisation including use anonymisation pseudonymisation appropriate (3) inquiry chair shall - (a) review policy procedure referred paragraph (1) regular basis (b) update policy procedure inquiry chair considers appropriate schedule inquiry licensing use sodium valproate woman childbearing potential state 350 5 term reference purpose focus inquiry purpose inquiry follows provide voice person diagnosis foetal valproate spectrum disorder (fvsd) progressing diagnostic pathway mother family member document regulation sodium valproate state initial licensing present day corresponding practice control place relating prescribing dispensing product woman child-bearing potential throughout time develop timeline significant development scientific knowledge relating teratogenicity sodium valproate ass irish health system current capacity respond disseminate implement measure address safety issue relating use sodium valproate woman child-bearing potential provide recommendation regarding consideration relevance anti-seizure medication (asms) ass adequacy service support currently provided diagnosed fvsd caregiver provide recommendation regarding identified international classification disease version 11 adopted assembly march 2019 defines fetal valproate spectrum disorder (code ld2f.03 ) fetal valproate spectrum disorder (fvsd) fetal valproate syndrome (fvs) describe range sign symptom occur consequence exposure sodium valproate valproic acid womb wide range physical anomaly occur increased frequency including spina bifida major minor limb abnormality oral clefting cardiac defect hypospadias joint laxity characteristic pattern facial dysmorphism frequently present especially notable early childhood neurodevelopmental problem including reduced iq poorer language motor development increased rate autistic spectrum disorder attention deficit hyperactivity disorder observed 40 exposed vision problem myopia astigmatism also common risk dose dependent impact brain may seen lower dos required physical development alteration 6 350 review phase establish timeline licensing use sodium valproate woman child-bearing potential emergence evidence regarding teratogenicity since first licensed state present day review following", "start_char": 3863, "end_char": 7971, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-1", "parent_doc_id": "si-2025-0350", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "1. Documentation on the licensing and regulation of sodium valproate", "text_raw": "1. Documentation on the licensing and regulation of sodium valproate \nfor use in women of child-bearing potential in the State and \nassociated safety reports.", "text_norm": "1 documentation licensing regulation sodium valproate use woman child-bearing potential state associated safety report", "start_char": 7971, "end_char": 8132, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-2", "parent_doc_id": "si-2025-0350", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "2. Reports and studies that have been conducted regarding the use and", "text_raw": "2. Reports and studies that have been conducted regarding the use and \nimpact in the State of sodium valproate in women of child-bearing \npotential.", "text_norm": "2 report study conducted regarding use impact state sodium valproate woman child-bearing potential", "start_char": 8132, "end_char": 8283, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-3", "parent_doc_id": "si-2025-0350", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "3. Any formal notifications alerting of safety concerns relating to the", "text_raw": "3. Any formal notifications alerting of safety concerns relating to the \n\nuse of this medicine in women of child-bearing potential.", "text_norm": "3 formal notification alerting safety concern relating use medicine woman child-bearing potential", "start_char": 8283, "end_char": 8417, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-4", "parent_doc_id": "si-2025-0350", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "4. Any guidance documents issued within the State for the use of this", "text_raw": "4. Any guidance documents issued within the State for the use of this \n\nmedicine in women of child-bearing potential.", "text_norm": "4 guidance document issued within state use medicine woman child-bearing potential", "start_char": 8417, "end_char": 8537, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-5", "parent_doc_id": "si-2025-0350", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "5. Work completed by the EMA to reduce valproate exposure in", "text_raw": "5. Work completed by the EMA to reduce valproate exposure in \npregnancy, particularly reports and recommendations issued in \n2014 and 2018 and implementation of same in the State.", "text_norm": "5 work completed ema reduce valproate exposure pregnancy particularly report recommendation issued 2014 2018 implementation state", "start_char": 8537, "end_char": 8719, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-6", "parent_doc_id": "si-2025-0350", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "6. Government commissioned reports published in the U.K. and other", "text_raw": "6. Government commissioned reports published in the U.K. and other \nEuropean jurisdictions concerning the use of sodium valproate in \nwomen of child-bearing potential. \n\n• \n\nIssue and review questionnaires to stakeholders to support this collation \nof information relating to sodium valproate. A list of suggested \nstakeholders is given in Appendix 1. \n\nOral statements \n\n• Following assessment of written submissions and documents, invite \nindividuals diagnosed with FVSD, their mothers and other family \nmembers who wish to engage with the inquiry to provide oral statements. \n\n• Document the impact and experience of sodium valproate on the lives of \nthose affected - both the women prescribed valproate in pregnancy and \nthose with a diagnosis of FVSD and their families. \n\n• At the Chair's discretion, other stakeholders may also be invited to attend \n\noral sessions, in separate sittings to patients and their families. \n\n \n \n \n \n\f[350] 7 \n\nAssessment of current systems and recommendation for improvements if \nidentified \n\n• Based on the documented experiences of women given during oral \nsessions and through written submissions, make recommendations as to \nhow communication and discussion of risks may be improved for any \nwoman prescribed sodium valproate. \n\n• Review current systems in place to ensure clear communication of risks \nto, and obtainment of informed consent from, women of child-bearing \nage who are prescribed sodium valproate. Make recommendations for \nimprovement if identified. \n\n• Review the controls in place regarding the prescribing and dispensing of \nsodium valproate to women of child-bearing age in the State including \nthe adequacy of same to support implementation of the approved \npregnancy prevention programme. Assess their adequacy and make \nrecommendations as to how these controls can be improved if identified. \n\n• Consider the relevance of recommendations made to the use of other \n\nASMs in women of child-bearing potential. \n\n• Being cognisant of the systems already in place for the dissemination of \nmedicines safety information, make recommendations as to how these \nsystems may be improved where risks are identified for use of ASMs \nduring pregnancy. \n\n• Consider the adequacy of services and supports currently provided to \nFVSD patients and their families, considering both statements submitted \nand information gathered by the inquiry. \n\n• Make any other recommendations considered appropriate by the Chair to \n\nsupport those with a diagnosis of FVSD. \n\nDeliverables and Associated Schedule \n\n• \n\n• \n\nInterim report to be provided to Minister within 6 months of the \ncommencement date of the inquiry, with update to those who have \nparticipated in the inquiry as relevant. \n\nInterim report will outline any assessments and recommendations made \nto that point, highlighting issues for immediate action that may become \napparent during the conduct of the review. \n\n• At this time, agree a date for provision of the final report to the Minister \nfor Health, ideally within 12 months but not later than 18 months after \nthe commencement of the inquiry. No further extension beyond 3 months \nwill be given beyond this agreed date. \n\nSubject to legal advice, stakeholders, including individuals and families who \nprovided oral statements will be provided with a confidential copy of the final \nreport by the Minister in advance of publication. \n\n \n \n \n\f8 [350] \n\nSuggested list of Stakeholders \n\nThe Chair may invite submissions from a range of stakeholders, including but \nnot limited to: \n\nStakeholder \nIndividuals and families with a diagnosis \nof FVSD \n\nIndividual bodies (if applicable) \n\n• HSE \n• OACS \n• Epilepsy Ireland \n\nOrganisation for Anticonvulsant \nSyndrome (OACS) Ireland \n\nn/a \n\nHealth Products Regulatory Authority \n(HPRA) \n\nn/a \n\nThe Health Service Executive (HSE) \n\nn/a \n\nThe Department of Health \n\n Sanofi \n\nn/a \n\n n/a \n\nPrescribers of sodium valproate \n\nIrish Medical Organisation \n\n• \n• Medical Council \n• \n\nIrish College of General \nPractitioners \n\n• HSE Clinical Leads \nfor Epilepsy and \nNeurology \n\n• College of Psychiatrists of \n\nIreland \n\nThe Pharmaceutical Society of Ireland \n\nn/a \n\nEpilepsy Ireland \n\nDisability Federation of Ireland \n\nn/a \n\nn/a \n\nForm and structure of inquiry proposed \n\nThe proposed non-statutory inquiry will be structured according to three separate \nstrands. The first strand will create a timeline for the use of sodium valproate in \nthe State in women of child-bearing potential including information on \nregulation, prescribing, dispensing and safety information issued. \n\nThe second strand of the inquiry will enable oral statements to be given by \nindividuals diagnosed with FVSD, their mothers and other family members who \nmay wish to participate in this inquiry. This will provide mothers, patients and \n\n \n\f[350] 9 \n\ntheir families with an opportunity to tell their story. These statements will be \nconsidered in the third phase by the Chair in developing recommendations on \nsupports for patients. \n\nOther stakeholders may also be invited to provide statements in separate \nsessions. All sessions will be held in private. \n\nThe third strand will involve the following: \n\n• An assessment of the current systems in place to respond, disseminate \nand implement measures that address safety issues relating to use of \nsodium valproate in women of child-bearing potential and to provide \nrecommendations for improvement of systems if identified. \n\n• Development of other recommendations based on the Chair’s assessment \n\nof:", "text_norm": "6 government commissioned report published u.k european jurisdiction concerning use sodium valproate woman child-bearing potential issue review questionnaire stakeholder support collation information relating sodium valproate list suggested stakeholder given appendix 1 oral statement following assessment written submission document invite individual diagnosed fvsd mother family member wish engage inquiry provide oral statement document impact experience sodium valproate life affected - woman prescribed valproate pregnancy diagnosis fvsd family chair discretion stakeholder may also invited attend oral session separate sitting patient family 350 7 assessment current system recommendation improvement identified based documented experience woman given oral session written submission make recommendation communication discussion risk may improved woman prescribed sodium valproate review current system place ensure clear communication risk obtainment informed consent woman child-bearing age prescribed sodium valproate make recommendation improvement identified review control place regarding prescribing dispensing sodium valproate woman child-bearing age state including adequacy support implementation approved pregnancy prevention programme ass adequacy make recommendation control improved identified consider relevance recommendation made use asms woman child-bearing potential cognisant system already place dissemination medicine safety information make recommendation system may improved risk identified use asms pregnancy consider adequacy service support currently provided fvsd patient family considering statement submitted information gathered inquiry make recommendation considered appropriate chair support diagnosis fvsd deliverable associated schedule interim report provided minister within 6 month commencement date inquiry update participated inquiry relevant interim report outline assessment recommendation made point highlighting issue immediate action may become apparent conduct review time agree date provision final report minister health ideally within 12 month later 18 month commencement inquiry extension beyond 3 month given beyond agreed date subject legal advice stakeholder including individual family provided oral statement provided confidential copy final report minister advance publication 8 350 suggested list stakeholder chair may invite submission range stakeholder including limited stakeholder individual family diagnosis fvsd individual body (if applicable) hse oacs epilepsy ireland organisation anticonvulsant syndrome (oacs) ireland n health product regulatory authority (hpra) n health service executive (hse) n department health sanofi n n prescribers sodium valproate irish medical organisation medical council irish college general practitioner hse clinical lead epilepsy neurology college psychiatrist ireland pharmaceutical society ireland n epilepsy ireland disability federation ireland n n form structure inquiry proposed proposed non-statutory inquiry structured according three separate strand first strand create timeline use sodium valproate state woman child-bearing potential including information regulation prescribing dispensing safety information issued second strand inquiry enable oral statement given individual diagnosed fvsd mother family member may wish participate inquiry provide mother patient 350 9 family opportunity tell story statement considered third phase chair developing recommendation support patient stakeholder may also invited provide statement separate session session held private third strand involve following assessment current system place respond disseminate implement measure address safety issue relating use sodium valproate woman child-bearing potential provide recommendation improvement system identified development recommendation based chair assessment", "start_char": 8719, "end_char": 14252, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-1", "parent_doc_id": "si-2025-0350", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "1. relevance of findings regarding current control systems for sodium", "text_raw": "1. relevance of findings regarding current control systems for sodium \nvalproate for other ASMs that may be used in women of childbearing potential, particularly if new evidence emerges.", "text_norm": "1 relevance finding regarding current control system sodium valproate asms may used woman childbearing potential particularly new evidence emerges", "start_char": 14252, "end_char": 14441, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-reg-2", "parent_doc_id": "si-2025-0350", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "2. services and supports for those diagnosed with FVSD", "text_raw": "2. services and supports for those diagnosed with FVSD \n\nas informed by information collated during the inquiry. \n\nThe scheduling of work across and within these strands will be at the discretion \nof the Chair of the inquiry. The Chair will be required to highlight any issues \nencountered in obtaining necessary documentation to the Minister, should they \narise during the inquiry. A record of this will be included in the reports prepared \nby the Chair. \n\nData Protection and Records Management \n\nThe inquiry should operate to the highest and most appropriate standards of data \nprotection and records management. The Chair will act as data processor, and, \nwith the Minister for Health, as joint data controller. The Minister may make \nregulations to enable the inquiry to process personal data and special categories \nof data. A Data Protection Impact Assessment will be put in place. Records \ncreated in the course of the conduct of the inquiry will be available to the \nMinister for Health. However, at the cessation of the inquiry, decisions will be \nmade regarding the disposal or retention of records, balancing data subject rights \nwith the Minister's obligations under the National Archives Act 1986 and \nRegulations 1988. \n\nSupporting Patient & Family Participation \n\nRegarding patients and families who choose to engage with the inquiry, it is \nacknowledged that this will be a difficult experience for many. It is considered \nby the Minister for Health that the participants, for reasons of their health and \nwellbeing, or due to their care commitments, or due to practical matters arising \nfrom their circumstances, may encounter barriers to participation. \n\nThe Minister for Health will ask the Chair to examine the provision of \nappropriate supports to enable participation. Counselling supports, a modest ex-\n\n \n \n\f10 [350] \n\ngratia payment, or reasonable support to access other professional advice, could \nbe considered by the Chair. While supports should be specific to the needs of the \ncohort of individuals participating in this inquiry, the Minister will ask the Chair \nto consider the supports provided to participants in the Scally Inquiry, and \nwhether a similar process could apply in this context. \n\nAny such supports will be put in place on a one-off basis, and are specific to this \nnon-statutory inquiry, it is not intended to set a precedent. However, in keeping \nwith the independence of their role, the Chair will make all final decisions as to \nhow best to establish and encourage participation with the inquiry. Further \ninformation on any supports being provided would be issued to participants upon \napplication to the inquiry. \n\nAs part of the establishment of the inquiry, the Chair will develop a strategic \nawareness campaign with the aim of achieving a high level of participation in \nthe inquiry. \n\nAppointment of a Chair \n\nThe Chair will be appointed by the Minister. The Chair will not have any \nconflicts of interest which could be seen as undermining the independence or \nintegrity of the inquiry. The Chair must be an appropriate person who is \ncompetent to carry out and manage the process of the inquiry in a timely manner, \nwhile giving due regard to the primacy of a person-centred, fair and independent \nprocess, and giving weight to all stakeholders and participants. The Chair must \nhave familiarity with the Health and Social Care services in the State. The Chair \nmay require, and must consider, independent and expert advice in relation to \nsome elements of the inquiry. The Chair must be able to evidence experience \nappropriate to the conduct of a non-statutory inquiry. \n\nRole of the Chair \n\n• The Chair shall conduct the inquiry independently in accordance with the \n\nTerms of Reference as set out above, and will: \n\n• With initial support from Department of Health, establish and \n\noperationalise the inquiry \n\n• With Department of Health support, and in consultation with \npatient groups, the Chair will provide appropriate supports to \nfacilitate the participation of patients and their families with this \ninquiry. In keeping with the independence of the role, the Chair \nwill make all final decisions as to how best to establish and \nencourage participation with the inquiry \n\n• Develop a strategic awareness campaign to promote participation \n\nin the inquiry \n\n• Conduct the review phase \n\n• Gather and assess statements from affected families \n\n• Gather and assess information and statements from other \n\nidentified stakeholders \n\n \n \n\f[350] 11 \n\n• Assess current systems and supports and make recommendations \n\nif identified \n\n• Produce the interim and final reports \n\n• The Chair will identify and set out such support and advice as they deem \nnecessary for the conduct of the inquiry, to be finalised by agreement \nwith the Minister for Health \n\n• Within the bounds of the Terms of Reference, the Chair will gather such \ninformation as they require in order to conduct an independent, fair and \nrigorous process \n\n• \n\nIn order to gather information relevant to the inquiry, the Chair shall act \nas a joint Data Controller with the Minister for Health, subject to an \nagreement to be put in place \n\n• The Chair will adhere to the legal basis for processing personal data and \nspecial categories of data as set out in the Data Protection Impact \nAssessment for the inquiry \n\n• The Chair will ensure that records formed as part of the conduct of the \ninquiry are managed appropriately, with arrangements made for retention \nor destruction of records as appropriate \n\nImplementation of Recommendations \n\nThe Department is committed to considering all recommendations made in the \nfinal report. After the final report is submitted to the Minister, a working group \nconsisting of relevant stakeholders will be established within 3 months to \nprovide quarterly progress reports on the implementation of accepted \nrecommendations of the inquiry. \n\nGIVEN under my Official Seal, \n\n21 July, 2025. \n\nJENNIFER CARROLL MACNEILL, \n\nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f12 [350]", "text_norm": "2 service support diagnosed fvsd informed information collated inquiry scheduling work across within strand discretion chair inquiry chair required highlight issue encountered obtaining necessary documentation minister arise inquiry record included report prepared chair data protection record management inquiry operate highest appropriate standard data protection record management chair act data processor minister health joint data controller minister may make regulation enable inquiry process personal data special category data data protection impact assessment put place record created course conduct inquiry available minister health however cessation inquiry decision made regarding disposal retention record balancing data subject right minister obligation national archive act 1986 regulation 1988 supporting patient family participation regarding patient family choose engage inquiry acknowledged difficult experience many considered minister health participant reason health wellbeing due care commitment due practical matter arising circumstance may encounter barrier participation minister health ask chair examine provision appropriate support enable participation counselling support modest ex- 10 350 gratia payment reasonable support access professional advice could considered chair support specific need cohort individual participating inquiry minister ask chair consider support provided participant scally inquiry whether similar process could apply context support put place one-off basis specific non-statutory inquiry intended set precedent however keeping independence role chair make final decision best establish encourage participation inquiry information support provided would issued participant upon application inquiry part establishment inquiry chair develop strategic awareness campaign aim achieving high level participation inquiry appointment chair chair appointed minister chair conflict interest could seen undermining independence integrity inquiry chair must appropriate person competent carry manage process inquiry timely manner giving due regard primacy person-centred fair independent process giving weight stakeholder participant chair must familiarity health social care service state chair may require must consider independent expert advice relation element inquiry chair must able evidence experience appropriate conduct non-statutory inquiry role chair chair shall conduct inquiry independently accordance term reference set initial support department health establish operationalise inquiry department health support consultation patient group chair provide appropriate support facilitate participation patient family inquiry keeping independence role chair make final decision best establish encourage participation inquiry develop strategic awareness campaign promote participation inquiry conduct review phase gather ass statement affected family gather ass information statement identified stakeholder 350 11 ass current system support make recommendation identified produce interim final report chair identify set support advice deem necessary conduct inquiry finalised agreement minister health within bound term reference chair gather information require order conduct independent fair rigorous process order gather information relevant inquiry chair shall act joint data controller minister health subject agreement put place chair adhere legal basis processing personal data special category data set data protection impact assessment inquiry chair ensure record formed part conduct inquiry managed appropriately arrangement made retention destruction record appropriate implementation recommendation department committed considering recommendation made final report final report submitted minister working group consisting relevant stakeholder established within 3 month provide quarterly progress report implementation accepted recommendation inquiry given official seal 21 july 2025 jennifer carroll macneill minister health 12 350", "start_char": 14441, "end_char": 20497, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
{"doc_id": "si-2025-0350-explanatory-note", "parent_doc_id": "si-2025-0350", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 350 of 2025", "title": "Act 2018 (No. 7 of 2018) and having duly complied with subsections (4) and (5)", "year": 2025, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThe purpose of these Regulations is to enable the commencement of the nonstatutory inquiry into the licensing and use of sodium valproate in women of \nchild-bearing potential in the State by providing a legislative base for the \ncontrolling and processing of personal data by the joint data controllers as \nrequired to fulfil the aims of the inquiry. \n\nThese Regulations revoke the Data Protection Act 2018 (Control of Data for the \nInquiry into the Historical Licensing and Use of Sodium Valproate) Regulations \n2024 (S.I. No. 752 of 2024). \n\n \n \n \n \n \n \n \n\f[350] 13 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€3.50 \n\n(DH-594) 30. 7/25. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) purpose regulation enable commencement nonstatutory inquiry licensing use sodium valproate woman child-bearing potential state providing legislative base controlling processing personal data joint data controller required fulfil aim inquiry regulation revoke data protection act 2018 (control data inquiry historical licensing use sodium valproate) regulation 2024 (s.i no 752 2024) 350 13 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur3.50 (dh-594) 30 7 25 propylon", "start_char": 20497, "end_char": 21664, "source_path": "downloads\\2025\\2025_0350.pdf", "extraction_method": "pdfminer", "checksum": "sha256:84c2b638e13f9c5f48dd36c5b0900b33412ac00dfc859b3e725d71ecc611f7a6", "cross_refs": []}
